Interleukin-6 (IL-6) Inhibitors - Therapeutics Pipeline 2017 - PowerPoint PPT Presentation

About This Presentation
Title:

Interleukin-6 (IL-6) Inhibitors - Therapeutics Pipeline 2017

Description:

The study analyzed that the IL-6 inhibitors therapeutics pipeline comprises approximately 18 active drug candidates in different stages of development. – PowerPoint PPT presentation

Number of Views:53

less

Transcript and Presenter's Notes

Title: Interleukin-6 (IL-6) Inhibitors - Therapeutics Pipeline 2017


1
Interleukin-6 (IL-6) Inhibitors Therapeutics
Pipeline to Witness Many Collaborations in Coming
Years
2
Interleukin-6 (IL-6) Inhibitors Therapeutics
IL-6 inhibitors therapeutics pipeline in 2017
The study analyzed that the IL-6 inhibitors
therapeutics pipeline comprises approximately 18
active drug candidates in different stages of
development. Interleukin-6 inhibitors acts on the
IL-6 receptor. IL-6 receptors belong to a group
of cytokine receptors that are expressed by
leukocytes and plays an important role in the
functioning of the immune system. It has a
characteristic role in systemic inflammation in
numerous disease conditions, including rheumatoid
arthritis, and psoriatic arthritis.
3
Interleukin-6 (IL-6) Inhibitors Therapeutics
Insights on pipeline segments
According to the research findings, most of the
drug candidates of the IL-16 inhibitors are being
developed as the monoclonal antibody. Access
Report Summary with Detailed TOC on
"Interleukin-6 (IL-6) Inhibitors Therapeutics
Pipeline Analysis, 2017 - Clinical Trials
Results, Patent, Designation, Collaboration, and
Other Developments at https//www.psmarketresear
ch.com/market-analysis/interleukin-6-inhibitors-th
erapeutics-pipeline
4
Interleukin-6 (IL-6) Inhibitors Therapeutics
Positive Clinical Results of IL-6 Inhibitors
Therapeutics Candidates
The positive clinical results from IL-6
inhibitors drug candidates have been driving the
pipeline growth. GlaxoSmithKline plc presented
results from two pivotal Phase III studies
(NCT01606761 NCT02019472) evaluating
subcutaneous sirukumab. In both the studies,
sirukumab met the primary endpoint showing
significant improvement in the signs and symptoms
of moderately to severely active rheumatoid
arthritis compared to placebo.
5
Interleukin-6 (IL-6) Inhibitors Therapeutics
Various collaborations for IL-6 Inhibitors
therapeutics drug development
In January 2017, Tiziana Life Sciences plc
acquired an exclusive world-wide license for
NI-1201, a fully human anti-IL-6R monoclonal
antibody (mAb), from Novimmune SA. In exchange
for the exclusive license from Novimmune SA,
Tiziana Life Sciences plc agreed to an upfront
cash payment, milestone payments, and a royalty
on future sales. Some of the key players
developing drugs for the treatment of IL-6
inhibitors therapeutics include GlaxoSmithKline
plc, Chugai Pharmaceutical Co., Ltd., Vitaeris
Inc. and others.
6
Interleukin-6 (IL-6) Inhibitors Therapeutics
Download report sample at
https//www.psmarketresearch.com/market-analysis/i
nterleukin-6-inhibitors-therapeutics-pipeline/repo
rt-sample
7
GET IN TOUCH
THANK YOU!
For information regarding permissions and other
queries Kindly write to
US/Canada Toll-Free 1-888-778-7886
Write a Comment
User Comments (0)
About PowerShow.com